SELLAS Life Sciences Group Inc Stock
SELLAS Life Sciences Group Inc gained 0.990% compared to yesterday.
The community is currently still undecided about SELLAS Life Sciences Group Inc with 0 Buy predictions and 2 Sell predictions.
With a target price of 1 € compared to the current price of 10.4 € the potential of -90.38% for SELLAS Life Sciences Group Inc would basically result in a total loss of the investment.
Our community identified positive and negative aspects for SELLAS Life Sciences Group Inc stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the SELLAS Life Sciences Group Inc stock. On the other hand our users think that "Innovation" could be a problem in the future.
SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Pros and Cons of SELLAS Life Sciences Group Inc in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of SELLAS Life Sciences Group Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 0.990% | 19.816% | -12.236% | 664.706% | 266.843% | 640.741% | 39.037% |
| Beximco Pharmaceuticals Ltd. GDR | 0.000% | -2.830% | 11.957% | 10.515% | 14.955% | 28.109% | -44.624% |
| Eledon Pharmaceuticals Inc. | -2.030% | 2.837% | -14.201% | -2.027% | 126.563% | 150.000% | -46.296% |
| Roche Holding AG | 0.200% | 2.573% | 6.692% | 43.899% | 9.626% | 62.033% | 62.033% |